Anti-inflammatory effect of the combination of a long acting beta2-agonist (salmeterol) and a corticosteroid (fluticasone propionate) on human airway epithelial cells following Staphylococcus aureus infection Source: Eur Respir J 2005; 26: Suppl. 49, 98s Year: 2005
Budesonide and fluticasone propionate exertdifferential effects on human bronchial epithelial cells exposed to streptococcus pneumoniae and viral mimetic Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016
Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2 -agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003
Differential effects of budesonide and fluticasone propionate on bacterial recognition receptors in COPD macrophages Source: International Congress 2016 – Airway response to infection Year: 2016
Differential effects of budesonide and fluticasone propionate on immune defense genes in human bronchial epithelium Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015
Effect of addition of salmeterol vs doubling the dose of fluticasone propionate on specific airway resistance in children with asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008
Corticosteroids and long-acting beta2 agonist combination restores the airway epithelial cell chloride efflux decreased by staphylococcus aureus supernatant Source: Annual Congress 2007 - Epithelial networks in the airways Year: 2007
The effects of treatment with fluticasone propionate alone and combination with salmeterol on asthma control and airway inflammation Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003
Combination of budesonide and formoterol is more effective in inhibiting GM-CSF production by bronchial epithelial cells than either drug alone Source: Eur Respir J 2003; 22: Suppl. 45, 457s Year: 2003
Effect of switching from high dose fluticasone propionate (FP) to FP/salmeterol (FSC) on airway inflammation in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 44s Year: 2004
In vivo dose response relation of inhaled fluticasone propionate (FP), adults with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
Inhibitory activities of fluticasone propionate and salmeterol on airway epithelial cell functions (FLIC24): adhesion molecule expression and cytokine release Source: Eur Respir J 2001; 18: Suppl. 33, 246s Year: 2001
The effects of inhaled corticosteroids and a beta-2 agonist on C. pneumoniae-infected airway epithelial cells Source: Virtual Congress 2020 – Translational science in respiratory infections Year: 2020
Long-term effect of salmeterol and fluticasone propionate on β2 -integrin mediated adhesion of neutrophils: role of annexin-1 in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 103s Year: 2006
Influence of formoterol alone and its fixed combination with budesonide on airway responsiveness and airway inflammation induced by repeated low dose allergen challenge Source: Eur Respir J 2007; 30: Suppl. 51, 749s Year: 2007
Inhibitory activity of fluticasone propionate (FP), on the constitutive or cytokine-induced bronchial epithelial cell (HBECs) functions in vitro Source: Eur Respir J 2003; 22: Suppl. 45, 76s Year: 2003
Anti-inflammatory effect and clinical efficacy of concomitant treatments to steroid inhaler in bronchial asthma: montelukast versus salmeterol Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006
Improved patient compliance with salmeterol/fluticasone propionate combination (SFC) compared with regular long-acting β2 agonist (LAB) and inhaled steroid (IS) therapy Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
The effect of salmeterol/fluticasone propionate (SFC) on bronchial mucosal neutrophils and IL-8 gene expression in COPD Source: Eur Respir J 2007; 30: Suppl. 51, 354s Year: 2007